Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
PALO ALTO, Calif. - The Food and Drug Administration approved Ranexa as a primary treatment for a kind of chest pain, maker CV Therapeutics Inc. said Thursday, adding to its earlier approval of the drug as a secondary treatment.
| CVTX | 9.23 |  -0.34 |
The FDA's decision will allow Ranexa to market the drug as an initial treatment for chronic angina. Previously it was approved only in patients who did not have success with other drugs. Angina is chest pain a person feels when his or her heart is not getting enough blood.
CV Therapeutics said Ranexa's label will indicate the drug can be used on its own or in combination with beta blockers and in other drugs. The packaging also will tout Ranexa's effects on other heart ailments and blood sugar control.
Sales of Ranexa totaled $66.7 million in 2007, a large majority of CV Therapeutics' revenue. The drug was launched in early 2006.
In premarket trading, CV Therapeutics shares climbed $1.30, or 13.4 percent, to $11. The stock finished at $9.70 on Wednesday.
You've heard the talk of "Green" throughout the whole of 2008, bu...
Lenovo, with its IdeaPad line series is previewing Y-Series IdeaPad Y650 laptops at CES in Las Vegas together with other new Ideapad Y-series.
After break the psychological resistance at 1.5000, yesterday the GBPUSD made a significant bullish momentum
Cisco will unveil new consumer products and initiatives during apress conference at the 2009 ...
Buy Real Estate, Tax Liens, and more- Fund your business or franchise without debt
Building your business and corporate credit for your small business.
Get your next web design project done with our los angeles web design team - Best web design with great price.
Partners   
|
© 2009 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
